Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, an ultrasound contrast agent used in ultrasound exams of the heart; TechneLite, a technetium generator that provides the essential nuclear material used in nuclear medicine procedures; and Xenon, a radiopharmaceutical gas used to assess pulmonary function and imaging cerebral blood flow. The company also offers Neurolite, an injectable that is used to identify the area in the brain where blood flow has been blocked or reduced due to stroke; and Cardiolite, an injectable technetium-labeled imaging agent used in myocardial perfusion imaging (MPI) procedures that assess blood flow distribution to the heart. In addition, it provides injectable radiopharmaceutical imaging agents, such as Thallium Tl 201 that is used in MPI studies to detect cardiovascular disease; Gallium Ga 67, which is used to detect various infections and cancerous tumors; FDG, a fluorine-18-radiolabeled imaging agent to identify and characterize tumors in patients undergoing oncologic diagnostic procedures; and Quadramet, a therapeutic product, which is used to treat severe bone pain associated with metastatic bone lesions. Further, the company is developing Flurpiridaz F 18, which is in Phase III clinical trials to assess blood flow to the heart; LMI 1195 that has completed Phase I clinical trials for assessing cardiac sympathetic nerve function; and LMI 1174, which is in pre-clinical development targeted to elastin in the arterial walls and atherosclerotic plaque. The company sells its products to hospitals, clinics, group practices, integrated delivery networks, group purchasing organizations, and radiopharmacies. Lantheus Holdings, Inc. was founded in 1956 and is headquartered in North Billerica, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:LNTH
Previous Symbol
CUSIPN/A
Phone978-671-8001
Debt
Debt-to-Equity Ratio4.76
Current Ratio3.50
Quick Ratio2.87
Price-To-Earnings
Trailing P/E Ratio17.34
Forward P/E Ratio20.16
P/E Growth4.05
Sales & Book Value
Annual Sales$331.38 million
Price / Sales2.01
Cash Flow$1.5745 per share
Price / Cash Flow11.01
Book Value$0.62 per share
Price / Book27.96
Profitability
EPS (Most Recent Fiscal Year)$1.00
Net Income$123.38 million
Net Margins36.75%
Return on Equity83.95%
Return on Assets8.22%
Miscellaneous
Employees483
Outstanding Shares38,470,000
Market Cap$670.45 million
OptionableOptionable
Lantheus (NASDAQ:LNTH) Frequently Asked Questions
What is Lantheus' stock symbol?
Lantheus trades on the NASDAQ under the ticker symbol "LNTH."
How were Lantheus' earnings last quarter?
Lantheus Holdings Inc (NASDAQ:LNTH) posted its earnings results on Tuesday, October, 30th. The medical equipment provider reported $0.24 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.18 by $0.06. The medical equipment provider earned $88.90 million during the quarter, compared to analysts' expectations of $83.53 million. Lantheus had a net margin of 36.75% and a return on equity of 83.95%. Lantheus's quarterly revenue was up 11.1% on a year-over-year basis. During the same period last year, the company posted $0.24 earnings per share. View Lantheus' Earnings History.
When is Lantheus' next earnings date?
What guidance has Lantheus issued on next quarter's earnings?
Lantheus issued an update on its FY 2018 earnings guidance on Tuesday, October, 30th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $337-342 million, compared to the consensus revenue estimate of $339.2 million.
What price target have analysts set for LNTH?
2 analysts have issued 1-year target prices for Lantheus' stock. Their forecasts range from $20.00 to $21.00. On average, they expect Lantheus' stock price to reach $20.50 in the next year. This suggests a possible upside of 18.3% from the stock's current price. View Analyst Price Targets for Lantheus.
What is the consensus analysts' recommendation for Lantheus?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lantheus in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Lantheus.
Has Lantheus been receiving favorable news coverage?
Media stories about LNTH stock have trended somewhat positive this week, according to InfoTrie. The research firm scores the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Lantheus earned a daily sentiment score of 1.8 on InfoTrie's scale. They also gave media stories about the medical equipment provider a news buzz of 3.0 out of 10, meaning that recent media coverage is unlikely to have an impact on the company's share price in the near future.
Who are some of Lantheus' key competitors?
Some companies that are related to Lantheus include Myriad Genetics (MYGN), Quidel (QDEL), Meridian Bioscience (VIVO), Intellia Therapeutics (NTLA), Oxford Immunotec Global (OXFD), Quotient (QTNT), Nymox Pharmaceutical (NYMX), Trinity Biotech (TRIB), Celldex Therapeutics (CLDX), Vermillion (VRML), ImmuCell (ICCC), Riot Blockchain (RIOT), Akers Biosciences (AKER), Achieve Life Sciences (ACHV) and Arca Biopharma (ABIO).
Who are Lantheus' key executives?
Lantheus' management team includes the folowing people:
- Ms. Mary Anne Heino, CEO, Pres & Director (Age 58)
- Mr. Michael P. Duffy, Sr. VP of Law & Public Policy, Gen. Counsel and Sec. (Age 57)
- Mr. John W. Crowley, Advisor (Age 54)
- Mr. Robert J. Marshall Jr., CFO & Treasurer
- Mr. John J. Bolla, Sr. VP of Technical Operations & Director
When did Lantheus IPO?
(LNTH) raised $75 million in an initial public offering (IPO) on Thursday, June 25th 2015. The company issued 7,900,000 shares at $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities served as the underwriters for the IPO and Baird was co-manager.
Who are Lantheus' major shareholders?
Lantheus' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (14.50%), Vanguard Group Inc (5.44%), Vanguard Group Inc. (5.44%), Vaughan Nelson Investment Management L.P. (3.50%), Dimensional Fund Advisors LP (3.41%) and Renaissance Technologies LLC (2.70%). Company insiders that own Lantheus stock include Avista Capital Partners Gp, Ll, Cesare Orlandi, David F Burgstahler, Derace L Schaffer, John W Crowley, Julie Mchugh, Mary Anne Heino, Michael P Duffy and Timothy G Healey. View Institutional Ownership Trends for Lantheus.
Which institutional investors are selling Lantheus stock?
LNTH stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., JPMorgan Chase & Co., JPMorgan Chase & Co., Vanguard Group Inc., Vanguard Group Inc, Fuller & Thaler Asset Management Inc., Vaughan Nelson Investment Management L.P. and Renaissance Technologies LLC. Company insiders that have sold Lantheus company stock in the last year include Cesare Orlandi, John W Crowley, Julie Mchugh, Michael P Duffy and Timothy G Healey. View Insider Buying and Selling for Lantheus.
Which institutional investors are buying Lantheus stock?
LNTH stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., LSV Asset Management, Raging Capital Management LLC, Gabelli Funds LLC, Cadence Capital Management LLC, Royce & Associates LP, Bank of New York Mellon Corp and Wells Fargo & Company MN. View Insider Buying and Selling for Lantheus.
How do I buy shares of Lantheus?
Shares of LNTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Lantheus' stock price today?
One share of LNTH stock can currently be purchased for approximately $17.3350.
How big of a company is Lantheus?
Lantheus has a market capitalization of $670.45 million and generates $331.38 million in revenue each year. The medical equipment provider earns $123.38 million in net income (profit) each year or $1.00 on an earnings per share basis. Lantheus employs 483 workers across the globe.
What is Lantheus' official website?
How can I contact Lantheus?
Lantheus' mailing address is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. The medical equipment provider can be reached via phone at 978-671-8001 or via email at [email protected]
MarketBeat Community Rating for Lantheus (NASDAQ LNTH)
MarketBeat's community ratings are surveys of what our community members think about Lantheus and other stocks. Vote "Outperform" if you believe LNTH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LNTH will underperform the S&P 500 over the long term. You may vote once every thirty days.
